# DESCRIPTION

## 1. INTRODUCTION

- introduce genome targeting

## 2. BACKGROUND OF THE INVENTION

- describe CRISPR/Cas system
- discuss genome editing specificity

## 3. SUMMARY OF THE INVENTION

- motivate treating prostate cancer
- outline genome editing method

## 5. DETAILED DESCRIPTION OF THE INVENTION

- introduce fusion genes

### 5.1 Fusion Genes

- define fusion gene
- describe TRMT11-GRIK2 fusion gene
- describe SLC45A2-AMACR fusion gene
- describe MTOR-TP53BP1 fusion gene
- describe LRRC59-FLJ60017 fusion gene
- describe TMEM135-CCDC67 fusion gene
- describe KDM4B-AC011523.2 fusion gene
- describe MAN2A1-FER fusion gene
- describe PTEN-NOLC1 fusion gene
- describe CCNH-C5orf30 fusion gene
- describe additional fusion genes

### 5.2 Fusion Gene Detection

- introduce fusion gene detection
- describe nucleic acid hybridization analysis
- describe fluorescent in situ hybridization (FISH) analysis
- describe additional detection methods

### 5.3 Methods of Treatment

- introduce methods of treatment
- describe targeted genome editing technique
- describe determining presence of fusion genes
- describe performing genome editing technique

### 5.4 Genome Editing Techniques

- introduce genome editing
- describe CRISPR/Cas 9 system
- explain use of guide RNAs
- detail endonuclease cleavage
- describe homologous recombination
- target fusion gene chromosomal breakpoint
- introduce donor nucleic acid sequence
- describe HSV-1 thymidine kinase
- explain ganciclovir administration
- introduce Cas9 mutations
- describe use of nickase
- detail targeting sequences
- explain homologous recombination with donor nucleic acid
- describe vector construction
- introduce adenovirus transduction

### 5.5 Kits

- introduce kits for treating subjects with fusion genes
- describe kit components for genome editing
- detail nucleic acid primers and probes
- explain FISH analysis
- describe PCR analysis
- introduce examples of kits

## 6. EXAMPLE 1: TRANSLOCATION AND FUSION GENE EVENTS IN PROGRESSIVE PROSTATE CANCER

### 6.1 Abstract

- motivate need for prostate cancer test
- state objective and design

### 6.2. Introduction

- describe prostate cancer challenge
- introduce whole genome sequencing
- hypothesize fusion genes association

### 6.3 Methods

- describe tissue samples
- outline whole genome sequencing library preparation
- detail whole genome sequencing
- explain read alignment
- describe fusion gene detection
- outline machine learning classifier
- describe RT-PCR and FISH validation

### 6.4. Results

- identify fusion genes by RNA and whole genome sequencing
- filter out non-prostate cancer specific fusion genes
- validate fusion genes through RT-PCR and sequencing
- describe fusion gene products and their potential functions
- perform fluorescence in situ hybridization to investigate fusion gene formation
- analyze FISH results to suggest genome recombination underlying fusion gene formation
- associate fusion genes with prostate cancer recurrence
- analyze clinical outcomes of prostate cancer patients with and without fusion genes
- build and test a prostate cancer prediction model using fusion gene data
- validate the prediction model on separate cohorts
- analyze the association of fusion genes with PSA doubling time and disease-free survival
- combine detection of fusion transcripts with clinical/pathological parameters to improve prediction rate

### 6.5. Discussion

- discuss the significance of fusion genes in prostate cancer
- speculate on the biological roles of fusion genes
- highlight two fusion genes of particular interest: MAN2A1-FER and SLC45A2-AMACR
- discuss the potential impact of fusion gene detection on clinical practice and future therapy

### 6.6. References

- list cancer statistics
- describe RNA-seq analysis
- introduce gene expression analysis
- discuss prostate cancer research
- summarize bioinformatics tools
- provide miscellaneous references

## 7. EXAMPLE 2: PTEN-NOLC1 FUSION GENES

- validate PTEN-NOLC1 fusion transcript
- investigate mechanism of PTEN-NOLC1 fusion transcript
- analyze clinical significance of PTEN-NOLC1 fusion

### 8. EXAMPLE 3: THERAPEUTIC TARGETING AT FUSION TRANSCRIPT CONTAINING CHIMERA PROTEIN MAN2A1-FER

- describe MAN2A1-FER fusion protein
- analyze expression of MAN2A1-FER in prostate cancer samples
- investigate effect of MAN2A1-FER on cell cycle entry
- analyze tyrosine phosphorylation of EGFR
- describe therapeutic targeting of MAN2A1-FER
- test Crisotinib on MAN2A1-FER expressing cells
- analyze effect of EGFR inhibitors on MAN2A1-FER expressing cells
- discuss MEK signaling in MAN2A1-FER oncogenic activity
- provide references for MAN2A1-FER
- describe additional references

### 9. EXAMPLE 4. ELIMINATION OF CANCER CELLS POSITIVE FOR FUSION TRANSCRIPTS THROUGH GENOME EDITING

- describe genome editing technology
- design guide RNA for breakpoint region
- construct donor DNA for genome editing
- test genome editing on cells with CCNH-C5orf30 and TMEM135-CCDC67 breakpoints

### 10. EXAMPLE 5: NOVEL FUSION TRANSCRIPTS ASSOCIATE WITH PROGRESSIVE PROSTATE CANCER

- discover novel fusion transcripts in prostate cancer samples
- validate fusion transcripts through Sanger sequencing
- describe ZMPSTE24-ZMYM4 fusion genes
- analyze motif of ZMPSTE24-ZMYM4 fusion
- describe CLTC-ETV1 fusion genes
- analyze motif of CLTC-ETV1 fusion
- describe ACPP-SEC13 fusion genes
- analyze motif of ACPP-SEC13 fusion
- describe DOCK7-OLR1 fusion genes
- analyze motif of DOCK7-OLR1 fusion
- describe PCMTD1-SNTG1 fusion genes

### 11. EXAMPLE 6: SLC45A2-AMACR FUSION GENES

- describe SLC45A2-AMACR fusion genes
- analyze motif of SLC45A2-AMACR fusion
- investigate SLC45A2-AMACR expression in prostate cancer samples
- study SLC45A2-AMACR-induced cell growth and transformation
- explore therapeutic targeting of SLC45A2-AMACR using racemase inhibitor

### 12. EXAMPLE 7: GENOME TARGETING AT THE CHROMOSOME BREAKPOINT OF A FUSION GENE RESULTED IN REMISSION OF XENOGRAFTED PROSTATE CANCERS

- motivate genome targeting
- describe vector construction
- outline in vitro Cas9 target cleavage assays
- detail cell culture and treatment
- describe FACS analysis
- describe tumor growth and spontaneous metastasis
- describe immunohistochemistry
- describe results of in vitro cleavage assays
- describe results of integration of EGFP-tk into TMEM135-CCDC67 breakpoint
- describe results of ganciclovir treatment
- describe results of xenografting and ganciclovir treatment
- motivate targeting fusion genes in cancer treatment
- describe advantages of genome therapeutic approach
- discuss limitations of current therapeutic approaches
- discuss potential of genome therapeutic approach
- describe specificity of CRISPR/Cas system
- discuss potential of EGFP-tk integration
- discuss potential of Cre expression
- discuss potential of genome therapeutic approach
- summarize results
- provide references

